Ruyi Huang

Fuma Road 420#
Fuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Fibrin-targeted photosensitizer aggregates significantly enhance the delivery of chemotherapeutic drugs to tumor vasculature.

Fibrin-targeted photosensitizer aggregates significantly enhance the delivery of chemotherapeutic drugs to tumor vasculature.

Journal: Biomaterials advances

Published: April 23, 2025

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

Journal: BMJ open

Published: January 20, 2025

Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer.

Targeting TRAP1-dependent metabolic reprogramming to overcome doxorubicin resistance in quiescent breast cancer.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: November 13, 2024

Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking.

Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking.

Journal: Technology and health care : official journal of the European Society for Engineering and Medicine

Published: March 22, 2024

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost-utility analysis in China and the United States.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost-utility analysis in China and the United States.

Journal: Frontiers in pharmacology

Published: March 21, 2024

Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma.

Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma.

Journal: Biochemical genetics

Published: October 25, 2023

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.

Journal: Clinical and experimental medicine

Published: November 15, 2022

Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.

Design, synthesis of novel triptolide-glucose conjugates targeting glucose Transporter-1 and their selective antitumor effect.

Journal: European journal of medicinal chemistry

Published: February 10, 2022

Design, synthesis and biological evaluation of new ganglioside GM3 analogues as potential agents for cancer therapy.

Design, synthesis and biological evaluation of new ganglioside GM3 analogues as potential agents for cancer therapy.

Journal: European journal of medicinal chemistry

Published: November 05, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026